Aquestive Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Aquestive Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-19.9%
Buyback Yield
| Total Shareholder Yield | -19.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Aquestive: Rare Opportunity With Dual Platform Strategy
Nov 05Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Sep 07
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aug 20Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AQST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AQST's dividend payments have been increasing.
Dividend Yield vs Market
| Aquestive Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AQST) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (AQST) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate AQST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AQST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AQST's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AQST has not reported any payouts.